The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04617743

Enrollment

500

Registered

2020-11-05

Start date

2020-11-26

Completion date

2022-11-01

Last updated

2026-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer Recurrent, Non-Invasive Bladder Urothelial Carcinoma

Keywords

bladder cancer, post voiding residual urine, recurrence, non-muscle invasive bladder cancer, progression

Brief summary

Although transurethral resection is the main treatment option for stage Ta and T1 disease, relapse is frequently detected. Tumor number, tumor size, T stage, presence of in situ carcinoma and tumor grade are risk factors for recurrence. The relationship between post voiding residual urine volume and bladder tumor recurrence and progression has not been clearly established. The investigators aimed to examine the effect of high post voiding residual urine volume on recurrence and progression based on the hypothesis that tumor cells circulating in the bladder may increase with excess residual urine.

Detailed description

Although transurethral resection is the main treatment option for stage Ta and T1 disease, relapse is frequently detected. Tumor number, tumor size, T stage, presence of in situ carcinoma and tumor grade are risk factors for recurrence. The relationship between post voiding residual urine volume and bladder tumor recurrence and progression has not been clearly established. Participants who underwent transurethral resection for bladder tumor will be included in the study. The investigators aimed to examine the effect of high post voiding residual urine volume on recurrence and progression based on the hypothesis that tumor cells circulating in the bladder may increase with excess residual urine.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with transitional cell non-muscle invasive bladder cancer (NMIBC) pathology * Patients with a diagnosis of Bladder cancer (NMIBC) * Patients undergoing transurethral resection for bladder cancer (NMIBC) * ≥18 years old patients

Exclusion criteria

* Non-transitional cell bladder cancers * Patients with muscle-invasive bladder cancer pathology * \<18 years old patients

Design outcomes

Primary

Measure	Time frame	Description
Recurrence	1 year	Non-muscle invasive bladder cancer recurrence rate

Secondary

Measure	Time frame	Description
Progression	1 year	Non-muscle invasive bladder cancer progression rate

Countries

Turkey (Türkiye)

Contacts

PRINCIPAL_INVESTIGATORMehmet Caglar Cakici, M.D.

Istanbul Medeniyet University

Outcome results